FX.co ★ Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment

Eisai Co., Ltd. and Biogen Inc. have announced the approval of LEQEMBI (lecanemab), a humanized monoclonal antibody targeting soluble aggregated amyloid-beta, by Mexico's Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) for the treatment of early-stage Alzheimer's disease. This treatment has already received approval and is being distributed in countries including the United States, Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain. The authorization of LEQEMBI is supported by data from the comprehensive global Phase 3 Clarity Alzheimer's disease study, where the treatment successfully achieved its primary objective and all critical secondary objectives with statistically meaningful results.